Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of tislelizumab + bevacizumab + second-line chemotherapy in RAS-mutant metastatic colorectal cancer
ChiCTR2200066728Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and bevacizumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: 6-month progression-free survival rate. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
tislelizumabbevacizumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2200066728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066728.